Tests DZD8586 against standard treatment in adults with returned chronic lymphocytic leukemia
Tests DZD8586 against other treatments in adults with chronic lymphocytic leukemia that has returned.
Plain-language title generated from the registry record
Registry title: A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Key facts
- Where
- Nanjing and Tianjin, ChinaSee the 2 sites
- Phase
- Phase 3
Where in China
- First Affiliated Hospital of Nanjing Medical University, Jiangsu Province HospitalNanjing, ChinaTaking people
- National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical CollegeTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dizal Pharmaceuticals
- Trial code
- NCT07139873EU 2025-522669-32-00
- Record updated
- 3 June 2026
- Original description
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy.Read full original descriptionShow less
A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 Versus Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy.
Primary objective of this study is to assess the efficacy using progression free survival assessed by independent review committee as primary endpoint. Approximately 250 participants are estimated to be randomized into the study.
Inclusion: Male and female participants ≥ 18 years of age; ECOG performance status 0-2; Confirmed diagnosis of relapsed or refractory CLL/SLL with indication for treatment; Adequate bone marrow reserve and organ system functions; Participants willing to comply with contraceptive restrictions.
Exclusion: Previous or current therapy and comedications meet exclusion criteria; Nausea and vomiting not controlled or chronic gastrointestinal diseases, unable to swallow the formulated product or previous bowel resection that would preclude adequate absorption; Participants with major cardiovascular disease, active infection, malignancy or uncontrolled systemic disease; History of hypersensitivity to active or inactive excipients of DZD8586 or drugs with a similar chemical structure or class; Any unresolved > Grade 1 adverse event at the time of starting study treatment; Known or suspected Richter transformation; Known or suspected CNS involvement; Women who are breast feeding.